Sounds like with saying funding through rest of year,
Sounds like with saying funding through rest of year, milestones could be after setup to come after, NP said part 3 might be December depending on FDA decisions. But to me having that funded secured helps with negotiations.
After this first domino falls for the US HIV market, I’m expecting the others coming much faster. NP said they will partner for the other major markets and now with the US market close to being determined, they have decided on the game plan. Until that decision was made, they would have keep all options available.
Also, I’m expecting them to partner with cancer. They don’t want to pay the full way like they did with HIV, and they will not have to. The FDA requiring to go with unmet need first in HIV forced their hand to wait until you have good data in the larger market for the best deal, which has been a blessing really in mono, allowing them to meticulously fine tune mono while working with combo.
Who was in the data room?
Potential partners in cancer
TNBC trial uses carboplatin—Pfizer
MCC trial uses Regorafenib—Bayer
Dr. Patterson seemed to indicate they have data showing leronlimab will allow
Opdivo and Keytuda to work again after they stop working within 3-6 months.
So Merck and BMS
Pfizer, Merck, and BMS are already testing ccr5 drugs in their cancer trials. So Bayer would be my guess, unless the others are far enough along to know, they want in on CytoDyn’s Ccr5/Cancer patents. And with the safety data of leronlimab, it’s hard for me to see competition similarly with any Ccr5 drugs in HIV, maraviroc of course being the only one approved.
5
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Nonprofit Models Shine Amid IRS Scrutiny Out in Oxnard, California, there's a brewing storm in the healthcare sector. No, it's not a billing error or yet another scandal. We're talking about a seismic shift that could poke holes in those tax-engineered Section 105(b) programs, all thanks to some hard-hitting IRS memoranda. The Nonprofit–TPA Model: A Safer Bet? Enter...
Continue Reading
Quantum Leap: Chattanooga's Bold Move So Chattanooga’s making waves again, folks. EPB just unveiled its new big shot, the IonQ Forte Enterprise quantum computer. That's right, they’ve slapped a commercial quantum computer and a networking hub together, right here in this Tennessee city. Is this a tech haven or what? Not to mention, it’s the first in America. A New...
Continue Reading
Big Moves in the Financial Advisory World Let's dive right in. Here's a real shakeup in the advisory realm: 28 financial advisors and team members from Sierra Ridge Advisor Group are packing their bags for Gateway Financial Partners. We're talking about a significant shift involving $825 million in assets under advisement. Instead of sticking with Sierra Ridge as it...
Continue Reading
Award-Winning Tool Headlines 2026 Beauty Scene There's a shake-up in the world of hair tools, folks. Bellissima's Diffon Supreme has snagged a 2026 Allure Best of Beauty Award for its prowess in taming the curly, wavy, and coily strands we all crave to manage. Performance Meets Innovation in Bellissima's Latest Let's not beat around the bush. The Diffon Supreme's trump...
Continue Reading
Young Artists Called to Inspire a Cancer-Free World What's the first image that pops into your head when you think of a world free from cancer? That's the magic question on deck for this year's Youth Art Contest by Debbie's Dream Foundation. Imaginations are set to run wild as the competition opens its gates to artists under 18, calling for visions splashed across...
Continue Reading
If you're a chocolate lover residing in or around the Portland area, you're in for a treat. The Portland Craft Chocolate Festival is back, running from October 2-4. This festival is not just any community event; it's going to be a massive chocolate bonanza featuring over 45 local chocolate artisans, bakers, and confectioners. And let me tell you, this year they’re...
Continue Reading
Unlikely Spotlight on Menopause at Capitol Hill If you told me a couple of years back that menopause would become a front-page political issue, I would've laughed. Yet, here we are, with over 125 advocates from 29 states converging on Washington, D.C., demanding legislative action on menopause. Why Menopause Matters in Policy The fact that more than half the population is...
Continue Reading
A Shift in Voter Expectations: Clear Actions Needed Arizona voters have spoken, and they aren't looking for the same old political song and dance anymore. They crave something meatier—action, not just words. Heading into the 2026 general election, folks in the Grand Canyon State are demanding concrete solutions and straightforward answers from those who seek to lead...
Continue Reading
Revolutionizing Viticulture with Data In today's wild world, climate change isn't just shifting weather patterns—it's upending the age-old map of wine-making regions. We've got a new player on the field: the World Winery Map. It's digital, massive, and it’s shaking things up for winemakers and grape enthusiasts alike. This platform covers a staggering 4.3 million...
Continue Reading
AI's Increasing Role: A Double-Edged Sword for Leaders Hey, the tech overlords remind us once again—the future doesn't wait for anyone to catch up before it bulldozes forward. Info-Tech Research Group has sounded the alarm on AI agents muscling their way into product decisions without any clear nod from the human corner office. Blurring Lines of Accountability The...
Continue Reading
Top 5 Most Recently Viewed Articles
A Bold Step into the Future of Smart Homes Hold onto your hats, folks! Haier is making waves at IFA 2026, showing off smart home tech that's not just buzzing with AI but adapting right before our eyes. 'Home of Intelligent Possibilities' isn't just a catchy phrase—it's Haier promising us homes that think for themselves. From laundry to cooking, they’re tweaking those...
Continue Reading
NSF Appoints Mel Cash as Chief Commercial Officer NSF, a leading global public health and safety organization, is excited to announce the addition of Melissa (Mel) Cash as its Vice President and Chief Commercial Officer. In her new position, Cash will lead initiatives aimed at driving growth in NSF’s global markets through innovative commercial strategies, enhanced...
Continue Reading
Transforming Peptide Drug Discovery with AI In a groundbreaking partnership, Atombeat Inc. and BioDuro are set to revolutionize the field of peptide drug discovery using an innovative AI-powered platform. This collaboration merges Atombeat's expertise in artificial intelligence with BioDuro's solid foundation in contract research, development, and manufacturing, aiming to...
Continue Reading
Meta Platforms Faces AI Challenges Against Competitors Steve Eisman, a well-known investor recognized for his predictions regarding significant market downturns, has brought attention to the competitive landscape of artificial intelligence (AI). He asserts that Meta Platforms Inc. (NASDAQ:META) is currently losing ground in a crucial AI battle against industry giants like...
Continue Reading
Whale Investment Dynamics in Union Pacific Whales, or large investors, have been making bold moves in the stock market, particularly with Union Pacific. Their bullish stance indicates significant confidence in the future of this major railroad company. Analyzing Options Activity for Union Pacific When we delve into Union Pacific (NYSE: UNP) options history, we've...
Continue Reading